Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.

Lake JA, Donson AM, Prince E, Davies KD, Nellan A, Green AL, Mulcahy Levy J, Dorris K, Vibhakar R, Hankinson TC, Foreman NK, Ewalt MD, Kleinschmidt-DeMasters BK, Hoffman LM, Gilani A.

Pediatr Blood Cancer. 2019 Oct 8:e28028. doi: 10.1002/pbc.28028. [Epub ahead of print]

PMID:
31595628
2.

Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma.

Grob S, Mirsky DM, Donson AM, Dahl N, Foreman NK, Hoffman LM, Hankinson TC, Mulcahy Levy JM.

Front Oncol. 2019 Aug 21;9:791. doi: 10.3389/fonc.2019.00791. eCollection 2019.

3.

Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.

Pierce AM, Witt DA, Donson AM, Gilani A, Sanford B, Sill M, Van Court B, Oweida A, Prince EW, Steiner J, Danis E, Dorris K, Hankinson T, Handler MH, Jones KL, Karam SD, Serkova NJ, Vibhakar R, Foreman NK, Griesinger AM.

Neuro Oncol. 2019 Jul 4. pii: noz116. doi: 10.1093/neuonc/noz116. [Epub ahead of print]

PMID:
31276586
4.

Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.

Donson AM, Amani V, Warner EA, Griesinger AM, Witt DA, Levy JMM, Hoffman LM, Hankinson TC, Handler MH, Vibhakar R, Dorris K, Foreman NK.

Mol Cancer Ther. 2018 Sep;17(9):1984-1994. doi: 10.1158/1535-7163.MCT-17-1185. Epub 2018 Jun 20.

5.

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, Manshaei S, Jani N, Hölsken A, Pettorini B, Beynon RJ, Simpson DM, Fraser HC, Hong Y, Hallang S, Stone TJ, Virasami A, Donson AM, Jones D, Aquilina K, Spoudeas H, Joshi AR, Grundy R, Storer LCD, Korbonits M, Hilton DA, Tossell K, Thavaraj S, Ungless MA, Gil J, Buslei R, Hankinson T, Hargrave D, Goding C, Andoniadou CL, Brogan P, Jacques TS, Williams HJ, Martinez-Barbera JP.

Acta Neuropathol. 2018 May;135(5):757-777. doi: 10.1007/s00401-018-1830-2. Epub 2018 Mar 14.

6.

Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

Coy S, Rashid R, Lin JR, Du Z, Donson AM, Hankinson TC, Foreman NK, Manley PE, Kieran MW, Reardon DA, Sorger PK, Santagata S.

Neuro Oncol. 2018 Jul 5;20(8):1101-1112. doi: 10.1093/neuonc/noy035.

7.

Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.

Witt DA, Donson AM, Amani V, Moreira DC, Sanford B, Hoffman LM, Handler MH, Levy JMM, Jones KL, Nellan A, Foreman NK, Griesinger AM.

Pediatr Blood Cancer. 2018 May;65(5):e26960. doi: 10.1002/pbc.26960. Epub 2018 Jan 19.

8.

Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.

Amani V, Donson AM, Lummus SC, Prince EW, Griesinger AM, Witt DA, Hankinson TC, Handler MH, Dorris K, Vibhakar R, Foreman NK, Hoffman LM.

J Neuropathol Exp Neurol. 2017 Jul 1;76(7):595-604. doi: 10.1093/jnen/nlx040.

9.

Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.

Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters BK, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC; Advancing Treatment for Pediatric Craniopharyngioma Consortium.

J Neuropathol Exp Neurol. 2017 Sep 1;76(9):779-788. doi: 10.1093/jnen/nlx061.

10.

p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.

Lummus SC, Donson AM, Gowan K, Jones KL, Vibhakar R, Foreman NK, Kleinschmidt-DeMasters BK.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26656. Epub 2017 May 26.

11.

A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.

Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26621. Epub 2017 May 24.

12.

NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma.

Griesinger AM, Witt DA, Grob ST, Georgio Westover SR, Donson AM, Sanford B, Mulcahy Levy JM, Wong R, Moreira DC, DeSisto JA, Balakrishnan I, Hoffman LM, Handler MH, Jones KL, Vibhakar R, Venkataraman S, Foreman NK.

Neuro Oncol. 2017 Oct 1;19(10):1350-1360. doi: 10.1093/neuonc/nox061.

13.

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.

Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, Kleinschmidt-DeMasters BK, Fitzwalter BE, Goodall ML, Thorburn J, Amani V, Donson AM, Birks DK, Mirsky DM, Hankinson TC, Handler MH, Green AL, Vibhakar R, Foreman NK, Thorburn A.

Elife. 2017 Jan 17;6. pii: e19671. doi: 10.7554/eLife.19671.

14.

Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.

Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R.

BMC Cancer. 2016 Aug 18;16:647. doi: 10.1186/s12885-016-2690-6.

15.

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.

Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R.

Oncotarget. 2016 Aug 16;7(33):53881-53894. doi: 10.18632/oncotarget.10692.

16.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.

Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P.

ACS Chem Biol. 2016 Jul 15;11(7):2066-7. doi: 10.1021/acschembio.6b00466. Epub 2016 Jun 15. No abstract available.

PMID:
27304454
17.

SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups.

Kleinschmidt-DeMasters BK, Donson AM, Richmond AM, Pekmezci M, Tihan T, Foreman NK.

J Neuropathol Exp Neurol. 2016 Apr;75(4):295-8. doi: 10.1093/jnen/nlw010. Epub 2016 Mar 4.

18.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.

Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P.

ACS Chem Biol. 2016 Apr 15;11(4):921-30. doi: 10.1021/acschembio.5b00725. Epub 2016 Jan 8. Erratum in: ACS Chem Biol. 2016 Jul 15;11(7):2066-7.

PMID:
26745241
19.

Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.

Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, Kleinschmidt-DeMasters BK, Johnston JM, Anderson RC, Rosenfeld A, Handler M, Gore L, Foreman N, Hankinson TC.

Acta Neuropathol Commun. 2015 May 21;3:30. doi: 10.1186/s40478-015-0211-5.

20.

Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK.

Cancer Immunol Res. 2015 Oct;3(10):1165-74. doi: 10.1158/2326-6066.CIR-15-0061. Epub 2015 May 12.

21.

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.

Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M, Pfister SM.

Cancer Cell. 2015 May 11;27(5):728-43. doi: 10.1016/j.ccell.2015.04.002.

22.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR.

J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.

23.

Pilomyxoid Astrocytoma (PMA) Shows Significant Differences in Gene Expression vs. Pilocytic Astrocytoma (PA) and Variable Tendency Toward Maturation to PA.

Kleinschmidt-DeMasters BK, Donson AM, Vogel H, Foreman NK.

Brain Pathol. 2015 Jul;25(4):429-40. doi: 10.1111/bpa.12239. Epub 2015 Jan 27.

24.

Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.

Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, Morgan MJ, Mirsky DM, Handler MH, Foreman NK, Thorburn A.

Cancer Discov. 2014 Jul;4(7):773-80. doi: 10.1158/2159-8290.CD-14-0049. Epub 2014 May 13.

25.

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R.

Mol Cancer. 2014 Mar 24;13:72. doi: 10.1186/1476-4598-13-72.

26.

Immunotherapeutic implications of the immunophenotype of pediatric brain tumors.

Griesinger AM, Donson AM, Foreman NK.

Oncoimmunology. 2014 Jan 1;3(1):e27256.

27.

Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.

Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH, Foreman NK.

Acta Neuropathol. 2014 May;127(5):731-45. doi: 10.1007/s00401-013-1212-8. Epub 2013 Nov 17.

28.

Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.

Donson AM, Kleinschmidt-DeMasters BK, Aisner DL, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ.

Brain Pathol. 2014 Mar;24(2):173-83. doi: 10.1111/bpa.12103. Epub 2013 Dec 23.

29.

Characterization of distinct immunophenotypes across pediatric brain tumor types.

Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK.

J Immunol. 2013 Nov 1;191(9):4880-8. doi: 10.4049/jimmunol.1301966. Epub 2013 Sep 27.

30.

Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors.

Neuwelt AJ, Nguyen T, Wu YJ, Donson AM, Vibhakar R, Venkatamaran S, Amani V, Neuwelt EA, Rapkin LB, Foreman NK.

Pediatr Blood Cancer. 2014 Jan;61(1):120-7. doi: 10.1002/pbc.24602. Epub 2013 Aug 17.

31.

Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma.

Backos DS, Fritz KS, McArthur DG, Kepa JK, Donson AM, Petersen DR, Foreman NK, Franklin CC, Reigan P.

Neurochem Res. 2013 Sep;38(9):1838-49. doi: 10.1007/s11064-013-1090-4. Epub 2013 Jun 7.

PMID:
23743623
32.

Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Barton VN, Donson AM, Birks DK, Kleinschmidt-DeMasters BK, Handler MH, Foreman NK, Rush SZ.

J Neuropathol Exp Neurol. 2013 May;72(5):442-9. doi: 10.1097/NEN.0b013e31829023dd.

33.

Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Birks DK, Donson AM, Patel PR, Sufit A, Algar EM, Dunham C, Kleinschmidt-DeMasters BK, Handler MH, Vibhakar R, Foreman NK.

Pediatr Blood Cancer. 2013 Jul;60(7):1095-102. doi: 10.1002/pbc.24481. Epub 2013 Feb 4.

34.

Emerging evidence of anti-tumor immune control in the central nervous system.

Donson AM, Foreman NK.

Oncoimmunology. 2012 Dec 1;1(9):1648-1649.

35.

Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.

Whiteway SL, Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Foreman NK, Vibhakar R.

J Neurooncol. 2013 Jan;111(2):113-21. doi: 10.1007/s11060-012-1000-7. Epub 2012 Nov 9.

36.

Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.

Donson AM, Birks DK, Schittone SA, Kleinschmidt-DeMasters BK, Sun DY, Hemenway MF, Handler MH, Waziri AE, Wang M, Foreman NK.

J Immunol. 2012 Aug 15;189(4):1920-7. doi: 10.4049/jimmunol.1103373. Epub 2012 Jul 16.

37.

Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas.

Sufit A, Donson AM, Birks DK, Knipstein JA, Fenton LZ, Jedlicka P, Hankinson TC, Handler MH, Foreman NK.

J Neurosurg Pediatr. 2012 Aug;10(2):81-8. doi: 10.3171/2012.3.PEDS11316. Epub 2012 Jun 29.

38.

Clinical and molecular characteristics of congenital glioblastoma.

Macy ME, Birks DK, Barton VN, Chan MH, Donson AM, Kleinschmidt-Demasters BK, Bemis LT, Handler MH, Foreman NK.

Neuro Oncol. 2012 Jul;14(7):931-41. doi: 10.1093/neuonc/nos125. Epub 2012 Jun 18.

39.

Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistry.

Chan MH, Kleinschmidt-Demasters BK, Donson AM, Birks DK, Foreman NK, Rush SZ.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1173-9. doi: 10.1002/pbc.24232. Epub 2012 Jun 15.

40.

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, Dubuc A, Taylor MD, Handler MH, Foreman NK, Vibhakar R.

BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.

41.

Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, Foreman NK, Liu AK, Vibhakar R.

J Neurooncol. 2012 May;107(3):517-26. doi: 10.1007/s11060-011-0795-y. Epub 2012 Jan 15.

42.

Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.

Knipstein JA, Birks DK, Donson AM, Alimova I, Foreman NK, Vibhakar R.

Neuro Oncol. 2012 Feb;14(2):175-83. doi: 10.1093/neuonc/nor208. Epub 2011 Dec 8.

43.

High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival.

Birks DK, Donson AM, Patel PR, Dunham C, Muscat A, Algar EM, Ashley DM, Kleinschmidt-Demasters BK, Vibhakar R, Handler MH, Foreman NK.

Neuro Oncol. 2011 Dec;13(12):1296-307. doi: 10.1093/neuonc/nor140. Epub 2011 Sep 23.

44.

Cytotoxicity of glioblastoma cells mediated ex vivo by varicella-zoster virus-specific T cells.

Canniff J, Donson AM, Foreman NK, Weinberg A.

J Neurovirol. 2011 Oct;17(5):448-54. doi: 10.1007/s13365-011-0048-z. Epub 2011 Jul 27.

45.

Survey of MicroRNA expression in pediatric brain tumors.

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK.

Pediatr Blood Cancer. 2011 Feb;56(2):211-6. doi: 10.1002/pbc.22723. Epub 2010 Nov 3.

PMID:
21157891
46.

Radiation-induced glioblastoma multiforme in children treated for medulloblastoma with characteristics of both medulloblastoma and glioblastoma multiforme.

Madden JR, Addo-Yobo SO, Donson AM, Liu AK, McNatt SA, Kleinschmidt-Demasters BK, Fenton LZ, Foreman NK, Smith AA.

J Pediatr Hematol Oncol. 2010 Oct;32(7):e272-8. doi: 10.1097/MPH.0b013e3181e51403.

PMID:
20736849
47.

Aurora kinase A as a rational target for therapy in glioblastoma.

Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R.

J Neurosurg Pediatr. 2010 Jul;6(1):98-105. doi: 10.3171/2010.3.PEDS10120.

PMID:
20593995
48.

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK.

Mol Cancer Ther. 2010 May;9(5):1298-307. doi: 10.1158/1535-7163.MCT-09-0707. Epub 2010 Apr 27.

49.

Tumor vaccination for malignant brain tumors.

Foreman NK, Donson AM.

Pediatr Blood Cancer. 2010 Apr;54(4):495-6. doi: 10.1002/pbc.22388. Review. No abstract available.

PMID:
19998471
50.

Immune gene and cell enrichment is associated with a good prognosis in ependymoma.

Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, Handler MH, Waziri AE, Wang M, Foreman NK.

J Immunol. 2009 Dec 1;183(11):7428-40. doi: 10.4049/jimmunol.0902811. Epub 2009 Nov 16.

Supplemental Content

Loading ...
Support Center